Supporting the local production of pharmaceuticals

Founded in 1949 by Abderrahim Bennis, Laprophan is a pioneering pharmaceutical company and nowadays stands as one of the undisputed leaders in the manufacturing, distribution, import and export of pharmaceutical products in Morocco. Laprophan distributes its own branded products and imported finished products from large international laboratories, providing patients and healthcare professionals with a wide range of medical drugs covering more than 40 specialties. Laprophan also exports its products to more than 30 countries across Africa and the Middle East and is an internationally renowned brand in the region.

Through this investment, the consortium aims to support Laprophan’s growth and expansion plans triggered by the recent generalization of Morocco’s compulsory health insurance scheme (AMO), which has doubled the number of beneficiaries in the last 12 months to reach 22 million people, and the growing demand for generic drugs in Morocco and Sub-Saharan African countries.

The project will improve the availability of drugs (41,700 people expected to benefit from access to drugs every year) in the context of the extension of medical insurance to the entire population of Morocco. It will also boost the local manufacturing base, by increasing production capacity, and support the creation of skilled jobs (including in laboratories and R&D), with 420 jobs created over the next 5 years and 7,850 jobs maintained.

The project should thereby contribute to the achievement of Sustainable Development Goal n° 3 (Good health and well-being), SDG 5 (Gender equality) and SDG 8 (Decent work and economic growth).